ClinicalTrials.gg
CompletedNCT02471183TRANSIT-1Updated Jan 23, 2018Results posted

Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Patients With Pulmonary Arterial Hypertension

A Phase 3 interventional study of Selexipag in Pulmonary Arterial Hypertension, sponsored by Actelion. Completed at 15 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-01-23.

Sponsored by Actelion (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
34
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing selexipag in Pulmonary Arterial Hypertension — 1 open to participants now, 3 under way, 1 of them phase 3. selexipag · Pulmonary Arterial Hypertension.

Enrollment
8th of 12
34 · median 67
Started
2015
the only one that year
Phase 3
6 of 12
1 open now
Registered
3rd of 12
by date
Lead sponsor
9 of 12
Actelion

Among the 12 studies testing selexipag in Pulmonary Arterial Hypertension, this one is the 8th largest by enrollment, is the only one that started in 2015, is one of 6 in phase 3, and was the 3rd registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

1 of the 12 studies testing selexipag in Pulmonary Arterial Hypertension is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About selexipag

selexipag: first FDA approval 2015 (UPTRAVI), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing selexipag in Pulmonary Arterial Hypertension, or all of them as a file.
02

Study summary

This study enrolls patients with pulmonary arterial hypertension (PAH) treated with inhaled treprostinil. During the study, the treatment with inhaled treprostinil will be tapered off and simultaneously replaced with an oral treatment (selexipag) targeting the disease in a similar way. The purpose of the study is i) to investigate the safety and tolerability of oral selexipag in patients who transition from inhaled treprostinil, ii) to investigate the effects of oral selexipag on PAH severity and exercise ability before and after transition, and iii) to gain new information about the patients experience taking oral selexipag compared to inhaled treprostinil. Study participants may stay in the study until the FDA has granted marketing authorization.

03

Conditions studied

  • Pulmonary Arterial Hypertension
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female patients aged from 18 to 75 years (inclusive) with pulmonary arterial hypertension (PAH).
  • Etiology of PAH belonging to one of the following subgroups: idiopathic PAH, Heritable PAH, drug or toxin induced, associated with connective tissue disease, associated with infection, associated with congenital heart disease with simple systemic-to-pulmonary shunt at least 1 year after surgical repair.
  • Women of are eligible only if the following apply: Negative serum pregnancy test at Visit 1 and a negative urine pregnancy test at Visit on Day 1, agreement to undertake monthly urine pregnancy tests during the study and up to 30 days after study drug discontinuation, agreement to use efficient methods of from Visit 1 up to at least 30 days after study treatment discontinuation.
  • Documented hemodynamic diagnosis of PAH by right heart catheterization (RHC).
  • Inhaled treprostinil treatment ongoing for at least 90 days and at stable dose for at least 30 days prior to Day 1.
  • WHO functional class (FC) II or III at Visit 1 and Visit 2.
  • 6-minute walk distance (6MWD) ≥ 300 m at Visit 1.
  • On background oral PAH therapy for at least 90 days and on a stable dose for 30 days prior to Visit 2. Acceptable concomitant PAH therapies are one or two of the following: a) Endothelin receptor antagonist (ERA), b) Phosphodiesterase type 5 (PDE-5) inhibitor or soluble guanylate cyclase (sGC) stimulator.

Exclusion criteria

Exclusion Criteria:

  • Treatment with any prostacyclin or prostacyclin analogs other than inhaled treprostinil within 90 days before Day 1, or patients scheduled to receive any of these treatments within the duration of the study.
  • Any hospitalization within 90 days before Day 1.
  • Worsening in WHO FC within 30 days prior to Day 1.
  • At any time prior to Day 1, documented moderate or severe obstructive or restrictive lung disease.
  • Known or suspicion of pulmonary veno-occlusive disease (PVOD).
  • Anemia: \< 80 g/L (5.0 mmol/L) .
  • thyroid disease (hypo- or hyperthyroidism).
  • Known and documented severe hepatic impairment.
  • Uncontrolled hypertension.
  • Sitting systolic blood pressure \< 85 mmHg.
  • Acute myocardial infarction within the last 90 days prior to Visit 1.
  • History of left-sided heart disease.
  • Left ventricular disease/dysfunction risk factors.
  • Documented pericardial effusion within 90 days prior to Visit 1.
  • Documented severe renal insufficiency.
  • Receiving or having received any drugs within 90 days before Day 1.
  • Having received selexipag at any time before Day 1.
  • Acute or chronic impairment (other than dyspnea), limiting the ability to comply with study requirements.
  • Recently conducted or planned cardio-pulmonary rehabilitation program based on exercise training during the study.
  • Psychotic, addictive or other disorder limiting the ability to provide or to comply with study requirements.
  • Known concomitant life-threatening disease with a \< 12 months.
  • Females who are lactating or pregnant or plan to become pregnant during the study.
  • Known to any of the of the drug formulation.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Selexipag, Open Label

    Subjects on inhaled treprostinil treatment participate in a 16-week main treatment period including down-titration of treprostinil to end of Week 8 and parallel up-titration of selexipag to the maximum tolerated dose (MTD) up to Week 12, for each individual patient but not above 1600 mcg twice daily. From Week 12 up to Week 16, patients continue selexipag at their individual MTD. Patients could continue the study drug selexipag during the extended treatment period from Week 16 until commercial availability of selexipag.

    Drug: Selexipag

Interventions

  • Tablets for oral administration containing 200 micrograms (mcg) of selexipag to be administered twice a day. The individual dose is to be established during the first 12 weeks of the study. Doses are in the range from 200 micrograms (1 tablet) to 1,600 micrograms (8 tablets).

    Also known as: Uptravi, ACT-293987

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects With Sustained Treatment Transition

    A sustained treatment transition is considered if the 3 following criteria are met a) being on study treatment (selexipag) at Week 16, and b) not having a study treatment interruption(s) of a total of 8 days or more prior to Week 16, and c) absence of inhaled treprostinil or any prostanoid treatment after Week 8 up to Week 16. The percentage of subjects with a sustained treatment transition is calculated with 95% confidence interval (CI) using the Clopper-Pearson method.

    Time frame: At Week 16

  2. Percentage of Subjects With Treatment-emergent Adverse Events (AEs),

    Percentage of subjects with treatment-emergent AEs (serious and non serious), regardless of relationship to selexipag

    Time frame: 26 weeks on average (from the first dose of selexipag up to 30 days after the last dose of selexipag)

  3. Number of Subjects With Adverse Events Leading to Premature Discontinuation of Selexipag

    Number of subjects with adverse events leading to premature discontinuation of selexipag is determined from the first dose of selexipag up to the last dose of selexipag

    Time frame: Up to 22 weeks on average

  4. Absolute Change From Baseline Over Time in Blood Pressure

    Both systolic(SBP) and diastolic (DBP) arterial blood pressure were measured in a sitting position after at least 5 minutes of rest at scheduled time points. Median change from baseline to pre-specified post-baseline visits are calculated

    Time frame: Baseline, Week 4, Week 12, Week 16

  5. Absolute Change From Baseline Over Time in Heart Rate (HR)

    Pulse rate is measured after at least 5 minutes of rest in a sitting position. Median change from baseline to pre-specified post-baseline visits are calculated.

    Time frame: Baseline, Week 4, Week 12, Week 16

  6. Maximal Tolerated Dose

    This is the individual maximal tolerated dose (MTD) observed at Week 12 in the subjects still on selexipag at Week 16. MTD is defined as the dose of selexipag reached with the last dose change up to Week 12

    Time frame: At Week 12, in subjects still on selexipag at Week 16

  7. Time to Discontinuation of Inhaled Treprostinil.

    Median time from baseline (Day1) to the end of down-titration of inhaled treprostinil is calculated

    Time frame: Baseline to Week 16

Secondary outcomes

  1. Percentage of Subjects With WHO Functional Class (FC) Change From Baseline

    The World Health Organization (WHO) defines 4 classes to classify the functional status of patients with pulmonary hypertension: Class I (FC I): No limitation of physical activity. Class II (FC II): Slight limitation of physical activity. Class III (FC III): Marked limitation of physical activity. Class IV (FC IV): Inability to carry out any physical activity without symptoms. Number of patients with improvement (shift from a higher to a lower class), worsening (shift from a lower to a higher class) or no change in WHO functional class at end of study compared to baseline are determined.

    Time frame: Baseline and Week 16

  2. Absolute Change in 6-minute Walk Distance (6MWD) at Trough

    The 6MWT is a non-encouraged test, which measures the distance (in meters) covered by the subject during a 6-minute walk. It is performed in a 30-meters long flat corridor, where the patient is instructed to walk as far as possible, back and forth around two cones, with the permission to slow down, rest, or stop if needed. Absolute change from baseline to Week 16 in 6MWD is measured at trough levels of inhaled treprostinil and/or selexipag. The trough level of inhaled treprostinil is defined as the last dose having been taken not less than 4 hours and not more than 48 hours prior to the 6MWT at Visit 1 (screening). The trough level of selexipag was defined as the last dose having been taken not less than 8 hours and not more than 7 days prior to the 6MWT at Visit 5 (Week 16).

    Time frame: Baseline and Week 16

  3. Percentage of Patients With Change in 6-minute Walk Distance (6MWD)

    Percentage of patients with an increase (\> 8% of baseline), maintenance (+/- 8% of baseline), or decrease (\< -8% of baseline) in their 6MWD (at trough) from baseline to Week 16. The ± 8% boundaries for change in 6MWD reflect the approximately 8% coefficient of variation in the reproducibility of the 6MWD. The trough level of inhaled treprostinil is defined as the last dose having been taken not less than 4 hours and not more than 48 hours prior to the 6MWD test at Visit 1 (screening). The trough level of selexipag was defined as the last dose having been taken not less than 8 hours and not more than 7 days prior to the 6MWD test at Visit 5 (Week 16).

    Time frame: Baseline and Week 16

  4. Geometric Mean of the Ratio in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) of Week 16 to Baseline

    Changes in NT-proBNP levels in plasma are expressed by the geometric mean of the ratio of Week 16 to baseline

    Time frame: Baseline and Week 16

Other outcomes

  1. Change From Baseline to Week 16 in the Treatment Satisfaction Questionnaire for Medication Questionnaire (TSQM II)

    The Treatment Satisfaction Questionnaire for Medication, Version II (TSQM II) is a validated tool that evaluate the subject's satisfaction with the study treatment. It includes a total of 11 questions related to satisfaction with treatment effectiveness, side effects,convenience, and global satisfaction. TSQM scores range from 0 to 100 for each domain; a higher score indicates higher satisfaction with treatment.

    Time frame: Baseline and Week 16

07

Results

Posted Dec 28, 2017

Participant flow

Thirty-seven patients were screened. Among them, thirty-four patients with pulmonary arterial hypertension (PAH) and treated with inhaled treprostinil for at least 90 days were enrolled at 12 sites in the USA.

Main Treatment Period
Participant flow — Main Treatment Period
MilestoneSelexipag
Started34
Completed32
Not completed2
Withdrew: Adverse event1
Withdrew: Withdrawal by subject1
Extended Treatment Period
Participant flow — Extended Treatment Period
MilestoneSelexipag
Started32
Completed31
Not completed1
Withdrew: Lack of efficacy1

Outcome measures

PrimaryPercentage of Subjects With Sustained Treatment Transition

A sustained treatment transition is considered if the 3 following criteria are met a) being on study treatment (selexipag) at Week 16, and b) not having a study treatment interruption(s) of a total of 8 days or more prior to Week 16, and c) absence of inhaled treprostinil or any prostanoid treatment after Week 8 up to Week 16. The percentage of subjects with a sustained treatment transition is calculated with 95% confidence interval (CI) using the Clopper-Pearson method.

Time frame:
At Week 16
Reported as:
Number · Percentage of participants
Percentage of Subjects With Sustained Treatment Transition
Percentage of participantsSelexipag
Percentage of Subjects With Sustained Treatment Transition82.4 (65.5 to 93.2)
PrimaryPercentage of Subjects With Treatment-emergent Adverse Events (AEs),

Percentage of subjects with treatment-emergent AEs (serious and non serious), regardless of relationship to selexipag

Time frame:
26 weeks on average (from the first dose of selexipag up to 30 days after the last dose of selexipag)
Reported as:
Number · Percentage of participants
Percentage of Subjects With Treatment-emergent Adverse Events (AEs),
Percentage of participantsSelexipag
Percentage of Subjects With Treatment-emergent Adverse Events (AEs),97.1
PrimaryNumber of Subjects With Adverse Events Leading to Premature Discontinuation of Selexipag

Number of subjects with adverse events leading to premature discontinuation of selexipag is determined from the first dose of selexipag up to the last dose of selexipag

Time frame:
Up to 22 weeks on average
Reported as:
Count of participants · Participants
Number of Subjects With Adverse Events Leading to Premature Discontinuation of Selexipag
ParticipantsSelexipag
Number of Subjects With Adverse Events Leading to Premature Discontinuation of Selexipag3
PrimaryAbsolute Change From Baseline Over Time in Blood Pressure

Both systolic(SBP) and diastolic (DBP) arterial blood pressure were measured in a sitting position after at least 5 minutes of rest at scheduled time points. Median change from baseline to pre-specified post-baseline visits are calculated

Time frame:
Baseline, Week 4, Week 12, Week 16
Reported as:
Median · mmHg
Absolute Change From Baseline Over Time in Blood Pressure
mmHgSelexipag
SBP change from baseline at week 41.00 (-32.0 to 59.0)
SBP change from baseline at week 12-3.00 (-28.0 to 35.0)
SBP change from baseline at week 16-4.00 (-24.0 to 25.0)
DBP change from baseline at week 4-3.00 (-26.0 to 34.0)
DBP change from baseline at week 12-4.00 (-30.0 to 48.0)
DBP change from baseline at week 16-6.00 (-21.0 to 15.0)
PrimaryAbsolute Change From Baseline Over Time in Heart Rate (HR)

Pulse rate is measured after at least 5 minutes of rest in a sitting position. Median change from baseline to pre-specified post-baseline visits are calculated.

Time frame:
Baseline, Week 4, Week 12, Week 16
Reported as:
Median · beats per minute (bpm)
Absolute Change From Baseline Over Time in Heart Rate (HR)
beats per minute (bpm)Selexipag
HR change from baseline at week 44.00 (-23.0 to 22.0)
HR change from baseline at week 126.00 (-34.0 to 33.0)
HR change from baseline at week 163.00 (-35.0 to 23.0)
PrimaryMaximal Tolerated Dose

This is the individual maximal tolerated dose (MTD) observed at Week 12 in the subjects still on selexipag at Week 16. MTD is defined as the dose of selexipag reached with the last dose change up to Week 12

Time frame:
At Week 12, in subjects still on selexipag at Week 16
Reported as:
Median · mcg
Maximal Tolerated Dose
mcgSelexipag
Maximal Tolerated Dose1200 (400 to 1600)
PrimaryTime to Discontinuation of Inhaled Treprostinil.

Median time from baseline (Day1) to the end of down-titration of inhaled treprostinil is calculated

Time frame:
Baseline to Week 16
Reported as:
Median · weeks
Time to Discontinuation of Inhaled Treprostinil.
weeksSelexipag
Time to Discontinuation of Inhaled Treprostinil.6.21 (1.0 to 14.9)
SecondaryPercentage of Subjects With WHO Functional Class (FC) Change From Baseline

The World Health Organization (WHO) defines 4 classes to classify the functional status of patients with pulmonary hypertension: Class I (FC I): No limitation of physical activity. Class II (FC II): Slight limitation of physical activity. Class III (FC III): Marked limitation of physical activity. Class IV (FC IV): Inability to carry out any physical activity without symptoms. Number of patients with improvement (shift from a higher to a lower class), worsening (shift from a lower to a higher class) or no change in WHO functional class at end of study compared to baseline are determined.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Subjects With WHO Functional Class (FC) Change From Baseline
percentage of participantsSelexipag
% subjects with WHO FC improvement26.5
% subjects with WHO FC worsening5.9
% subjects with WHO FC unchanged67.6
SecondaryAbsolute Change in 6-minute Walk Distance (6MWD) at Trough

The 6MWT is a non-encouraged test, which measures the distance (in meters) covered by the subject during a 6-minute walk. It is performed in a 30-meters long flat corridor, where the patient is instructed to walk as far as possible, back and forth around two cones, with the permission to slow down, rest, or stop if needed. Absolute change from baseline to Week 16 in 6MWD is measured at trough levels of inhaled treprostinil and/or selexipag. The trough level of inhaled treprostinil is defined as the last dose having been taken not less than 4 hours and not more than 48 hours prior to the 6MWT at Visit 1 (screening). The trough level of selexipag was defined as the last dose having been taken not less than 8 hours and not more than 7 days prior to the 6MWT at Visit 5 (Week 16).

Time frame:
Baseline and Week 16
Reported as:
Median · meters
Absolute Change in 6-minute Walk Distance (6MWD) at Trough
metersSelexipag
Absolute Change in 6-minute Walk Distance (6MWD) at Trough-10.25 (-25.60 to 8.80)
SecondaryPercentage of Patients With Change in 6-minute Walk Distance (6MWD)

Percentage of patients with an increase (\> 8% of baseline), maintenance (+/- 8% of baseline), or decrease (\< -8% of baseline) in their 6MWD (at trough) from baseline to Week 16. The ± 8% boundaries for change in 6MWD reflect the approximately 8% coefficient of variation in the reproducibility of the 6MWD. The trough level of inhaled treprostinil is defined as the last dose having been taken not less than 4 hours and not more than 48 hours prior to the 6MWD test at Visit 1 (screening). The trough level of selexipag was defined as the last dose having been taken not less than 8 hours and not more than 7 days prior to the 6MWD test at Visit 5 (Week 16).

Time frame:
Baseline and Week 16
Reported as:
Number · Percentage of participants
Percentage of Patients With Change in 6-minute Walk Distance (6MWD)
Percentage of participantsSelexipag
6MWD decreased26.5
6MWD maintained55.9
6MWD increased17.6
SecondaryGeometric Mean of the Ratio in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) of Week 16 to Baseline

Changes in NT-proBNP levels in plasma are expressed by the geometric mean of the ratio of Week 16 to baseline

Time frame:
Baseline and Week 16
Reported as:
Geometric mean · Geometric mean of the ratio
Geometric Mean of the Ratio in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) of Week 16 to Baseline
Geometric mean of the ratioSelexipag
Geometric Mean of the Ratio in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) of Week 16 to Baseline1.1 (0.82 to 1.62)
Other pre-specifiedChange From Baseline to Week 16 in the Treatment Satisfaction Questionnaire for Medication Questionnaire (TSQM II)

The Treatment Satisfaction Questionnaire for Medication, Version II (TSQM II) is a validated tool that evaluate the subject's satisfaction with the study treatment. It includes a total of 11 questions related to satisfaction with treatment effectiveness, side effects,convenience, and global satisfaction. TSQM scores range from 0 to 100 for each domain; a higher score indicates higher satisfaction with treatment.

Time frame:
Baseline and Week 16
Reported as:
Median · Units on a scale
Change From Baseline to Week 16 in the Treatment Satisfaction Questionnaire for Medication Questionnaire (TSQM II)
Units on a scaleSelexipag
Effectiveness (change from baseline)0.00 (-8.3 to 8.3)
Side effects (change from baseline)0.00 (-16.7 to 0.0)
Convenience (change from baseline)44.44 (27.8 to 61.1)
Global satisfaction (change from baseline)8.33 (0.0 to 25.0)

Adverse events

Collected over From study treatment initiation up to 30 days after study treatment discontinuation. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Selexipag0/34 (0%)2/34 (5.9%)33/34 (97.1%)
Most frequent serious events
Most frequent serious events
EventSelexipag
Generalised tonic-clonic seizureNervous system disorders1/34
Muscle haemorrhageMusculoskeletal and connective tissue disorders1/34
NauseaGastrointestinal disorders1/34
SyncopeNervous system disorders1/34
VomitingGastrointestinal disorders1/34
Most frequent other events
Showing 10 of 34
Most frequent other events
EventSelexipag
HeadacheNervous system disorders27/34
DiarrhoeaGastrointestinal disorders24/34
Pain in jawMusculoskeletal and connective tissue disorders16/34
DyspnoeaRespiratory, thoracic and mediastinal disorders11/34
MyalgiaMusculoskeletal and connective tissue disorders9/34
FatigueGeneral disorders8/34
FlushingVascular disorders8/34
DizzinessNervous system disorders7/34
NauseaGastrointestinal disorders7/34
Pain in extremityMusculoskeletal and connective tissue disorders7/34

Baseline characteristics

Age, Customized
Age, Customized(Participants)Selexipag
Age categories as per protocol — <= 65 years28
Age categories as per protocol — >65 years and <75 years5
Age categories as per protocol — >= 75 years1
Sex: Female, Male
Sex: Female, Male(Participants)Selexipag
Female28
Male6
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Selexipag
Race categories as per protocol — Black or African American2
Race categories as per protocol — Asian3
Race categories as per protocol — White28
Race categories as per protocol — Other1
Etiology of pulmonary arterial hypertension (PAH)
Etiology of pulmonary arterial hypertension (PAH)(Participants)Selexipag
Idiopathic19
Heritable0
Drug or toxin induced5
Associated PAH10
World Health Organization Functional class (WHO FC)
World Health Organization Functional class (WHO FC)(Participants)Selexipag
FC I0
FC II25
FC III9
FC IV0
Time since initial inhaled treprostinil
Time since initial inhaled treprostinil(Months)Selexipag
Median37.8 (4.4 to 135.2)
Treprostinil stable dose
Treprostinil stable dose(Participants)Selexipag
< 54 mcg q.i.d.2
54 mcg q.i.d.20
> 54 mcg q.i.d.12
PAH-specific therapy at baseline
PAH-specific therapy at baseline(Participants)Selexipag
PDE5-inhibitors alone7
ERAs alone4
ERAs and PDE-519
ERAs and sCG stimulator4
08

Study locations

15 sites
  • UCSD Medical Center -La Jolla
    La Jolla, California, United States
  • UCSF Medical Center
    San Francisco, California, United States
  • Harbor UCLA Medical Center
    Torrance, California, United States
  • Emory University
    Atlanta, Georgia, United States
  • Piedmont Healthcare Research Institute
    Austell, Georgia, United States
  • Kentuckiana Pulmonary Associates
    Louisville, Kentucky, United States
  • University of Michigan Health System
    Ann Arbor, Michigan, United States
  • Washington University School of Medicine
    Saint Louis, Missouri, United States
  • Duke Unversity
    Durham, North Carolina, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania, United States
  • Allegheny General Hospital
    Pittsburgh, Pennsylvania, United States
  • University of Pittsburgh Medical Center Health System
    Pittsburgh, Pennsylvania, United States
  • UT Southwestern
    Dallas, Texas, United States
  • Houston Methodist Hospital
    Houston, Texas, United States
  • Sentara Cardiovascular Research Instistute
    Norfolk, Virginia, United States
09

References and documents

Publications

  • Frost A, Janmohamed M, Fritz JS, McConnell JW, Poch D, Fortin TA, Miller CE, Chin KM, Fisher M, Eggert M, McEvoy C, Benza RL, Farber HW, Kim NH, Pfister T, Shiraga Y, McLaughlin V. Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study. J Heart Lung Transplant. 2019 Jan;38(1):43-50. doi: 10.1016/j.healun.2018.09.003. Epub 2018 Sep 12. PubMed 30391194 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2015 to primary completion in Dec 2016, 13 months.

Results were first posted in Dec 2017, 1 year after primary completion.

Of 43 industry-sponsored phase 3 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 83. This study's 13 months is below that.

Counting every sponsor, half of 49 studies reached it within 50 months; a quarter within 31 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2015
First posted
Jun 15, 2015
StartActual
Oct 12, 2015
Primary completionActual
Dec 5, 2016
CompletionActual
Dec 5, 2016
Results first posted
Dec 28, 2017
Last update
Jan 23, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02471183
Lead sponsor
Actelion
Responsible party
Sponsor
First posted
Jun 15, 2015
Start date
Oct 12, 2015
Primary completion
Dec 5, 2016
Completion
Dec 5, 2016
Results posted
Dec 28, 2017
Last update
Jan 23, 2018

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selexipag

Start the discussion